VIR's T-cell engagers have potential in oncology and showed promise with initial data in January 2025. Read my thoughts about VIR's near-term catalysts.

Arizona State Retirement System lessened its stake in Vir Biotechnology, Inc. (NASDAQ:VIR – Free Report) by 6.3% in the 4th ...

the estimate revisions trend for Vir Biotechnology: mixed. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current ...

Vir Biotechnology (NASDAQ:VIR – Get Free Report)‘s stock had its “buy” rating restated by investment analysts at HC Wainwright in a research note issued to investors on Friday,Benzinga reports. They ...

Explore Vir Biotechnology stock price, quotes, charts and forecasts with Benzinga. Stay updated on market trends for VIR. Vir Biotechnology's Phase 1 data highlights early promise for T-cell ...

"2024 was a year of transformation for Vir Biotechnology as we successfully defined and executed on our renewed strategic direction, focusing our resources on our most promising programs in ...

Short interest in Vir Biotechnology Inc (NASDAQ:VIR) increased during the last reporting period, rising from 7.64M to 7.67M. This put 9.04% of the company's publicly available shares short.

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Irhythm Technologies (IRTC – Research Report), Vir Biotechnology (VIR – Research Report) and Biogen (BIIB ...

With the company's upcoming earnings report due on February 20, InvestingPro subscribers can access 7 additional key insights about VIR's financial health and valuation status. The sale was ...

VIR), today announced that the Company will provide a corporate update and report financial results for the fourth quarter and full year ended December 31, 2024, on February 26, 2025. The Company ...

Vir Biotechnology has enrolled the first subject in the Phase III ECLIPSE registrational programme of tobevibart and elebsiran in individuals with chronic hepatitis delta (CHD), an inflammatory ...